Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

The global analysis included 3905 randomized patients and showed an aggregated superior clinical success rate of moxifloxacin of 1.5% (95% CI = −0.4%–3.4%) which did not reach statistical significance, but showed a trend towards a better clinical outcome with moxifloxacin (Figure 2 ).

also in 53,322 other papers